Amgen Inc. (NASDAQ:AMGN) is highlighted as one of the 11 Dogs of the Dow Dividend Stocks to Buy Now. The company is focused on developing breakthrough drugs to stay ahead of biosimilar competition, with a strong pipeline of programs expected to drive future growth and innovation.

In the first quarter of 2025, Amgen Inc. (NASDAQ:AMGN) reported strong earnings with revenue reaching $8.15 billion, a 9.4% increase year-over-year. The company’s robust cash flow of $1.0 billion and dividend yield of 3.11% make it a reliable investment option, with dividends consistently raised since 2011.

Amgen Inc. (NASDAQ:AMGN) offers a quarterly dividend of $2.38 per share and recently doubled its free cash flow to $1.0 billion. The company’s strong performance and track record of dividend growth position it as one of the best dogs of the Dow, with a focus on long-term growth prospects and shareholder returns.

Read more at Yahoo Finance: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick